Aurora Cannabis is the world’s largest cannabis-producing company with target output of over 500,000 kilos per year, & now the company calls for patient-focused progression in Europe.
The opportunity for cannabis companies in operating in Europe as has been highlighted by the chief corporate officer of the world’s largest cannabis company, Aurora Cannabis. Cam Battley of Aurora Cannabis spoke at the inaugural European Cannabis Week in London last week and called for patient-focused progression in the European regulatory environment.
The European market
Aurora Cannabis is the world’s largest cannabis-producing company with a target output of over 500,000 kilos per year, operations in 24 countries and a market capitalisation of $7.7 billion (~€8.6 billion).
Despite Europe being late to the party and lacking standardisation, the continent is seeing an increase in demand for medical cannabis. To meet this demand, according to Aurora, the company has established a number of operations in Europe including a one million square ft Danish production facility that utilises some of the highest levels of agriculture technology anywhere in the world.
“We’re the only ones in the world who have created mass scale facilities that are indoor”
Battley says: “What sets Aurora apart from all of our peers is our technology, our culture, and particularly I would say our medical focus and expertise, and investment in our clinical programme.
“Our cultivation technology is unique in the world, we’re the only ones in the world who have created mass scale facilities that are indoor with positive pressure, just like in pharmaceutical manufacturing, and they produce enormous amounts of Cannabis at very high volume, and at very low cost.”
As well as the production of Cannabis, Aurora invests significantly into research and development involving clinical trials focusing on patient experience. The engagement in R&D is arguably preparing Aurora for the next chapter in European cannabis acceptance.
